Ann: Market Update - PAT-DX1 Clinical Trial Preparation, page-224

.Antibodies are revolutionising cancer therapies with their ability in binding to certain targets. Most antibody therapies can only bind to markers on the cell surface as they can’t penetrate the cell membrane. This leads to a wide range of intracellular targets ( located or occurring within a cell) inaccessible to antibody therapies .

Previous antibody therapies have targeted and attacked markers on the cancer cell but have resulted in toxic side effects when the antibody attacks healthy cells.
.Patry’s Aka PAB a Melbourne-based biotech company, is overcoming these limitations by developing cell-penetrating antibodies (Deoxymabs) a completely new antibody-based technology that targets tumors, penetrates cells, binds to DNA and blocks DNA repair. .

Patry’s Deoxymab PAT-DX1 can accumulate at tumours, then penetrate into the cells to engage the targets that other antibodies can’t reach.

PAT-DX1 is a DNA antibody that hones in on tumours because it’s attracted to the swarm of extra cellular DNA released from dead and dying cancer cells. Once PAT-DX1 penetrates into the cell nucleus (centre of cell), deoxymabs bind to damaged DNA, blocking the cells DNA damage repair (DDR) systems. Cells with damaged DNA are not able to divide and usually self-destruct. Cancer therapies, such as radiation and a number of chemo drugs, work by damaging DNA and can be made more effective by combining them with drugs that also block DDR.

PAT-DX1 Brain cancer animal studies which were conducted at Yale University has seen -Tumour sizes reduced. -increased survival by 47% -71% increased survival when PAT- DX1 is combined with radiation therapy. Pretty amazing considering there isn’t currently a strong survival rate for brain cancer sufferers. PAT-DX1 is able to significantly inhibit the growth of tumours in three different models of cancer once it crosses the BBB ( blood brain barrier) .

CEO Dr James Campbell has been successfully involved in multi million dollar Licensing deals and has been involved in two companies that were sold after 2 pivotal phase 2 trial and have 2 products on the market.He mentions in an interview about the expertise that the board brings, for example Pam Klein who lead a team at Genentech with their product Herceptin, which is the most successful anti cancer of antibodies. She’s on the board of European company Argenx which is an antibody development company worth more then $10 billion dollars.